Will Korean bio stocks rebound as MSCI includes Celltrion, Viromed, HLB?
기사승인 2018.05.16 11:25:14
Marian Chu yjc@docdocdoc.co.kr
- 1Hospital‘Additional cochlear implants best done before the age of 3’
- 2PharmaGtree presents dry eye treatment at US conference
- 3Pharma‘Sanofi Korea’s Dupixent has low possibility of reimbursement’
- 4BioKolon unveils trial results for Invossa at cartilage repair conference
- 5PharmaNovartis embroiled in another illegal kickback allegation
- 6PharmaAbbvie applies for European marketing approval for investigational psoriasis therapy
- 7PharmaJW Pharma, Syntekabio agree to develop new drugs using AI
set_C1
